You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023376026
Dec 202392016
Jan 20245508
Feb 20245205
Mar 20248407
Apr 20248405
May 202484011
Jun 20247703
Jul 202410007
Aug 20248209
Sep 20246608
Oct 20244605
Nov 20245009
Dec 202498028
Jan 202572014
Feb 202521013
Mar 2025005
Apr 20251012
May 2025004
Jun 2025105
Total14410200